Skip to main content
Clinical Trials/TCTR20211111002
TCTR20211111002
Completed
Phase 3

A study of onabotulinum toxin type A for the treatment of ultraviolet B-induced hyperpigmentation: a prospective, randomized, controlled trial

Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital0 sites15 target enrollmentNovember 11, 2021

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
VB-induced hyperpigmentation
Sponsor
Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital
Enrollment
15
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 11, 2021
End Date
October 29, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital

Eligibility Criteria

Inclusion Criteria

  • Healthy subjects older than 18\-year\-old

Exclusion Criteria

  • the subjects who have the serious underlying diseases, pregnancy, active skin diseases, allergic reaction to BoNT\-A, history of photosensitive disorders, and ongoing use of topical medications or laser procedures at the experimental sites

Outcomes

Primary Outcomes

Not specified

Similar Trials